The relationshipbetween bilirubin and ESSDAI was analyzed by Spearman's correlation analysis and multivariable logistic regression.Results: The median level of serum bilirubin was 9 μmol/L (interquartile range (IQR), 7-13 μmol/L) in pSS patients, much lower than healthy controls(median, IQR, 13, 10-18 μmol/L) (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objectives: This study aims to determine the serum bilirubin levels in primary Sjögren's syndrome (pSS) patients and to explore clinical significanceof bilirubin in pSS.Patients and methods: Retrospective analysis of electronic medical records was performed in 97 pSS patients (12 males, 85 females; mean age54±15 years; range, 15 to 91 years) and 100 healthy controls (17 males, 83 females; mean age 51±14 years; range, 25 to 75 years).
📊
Key Findings & Data:The European League Against Rheumatism Sjögren's syndrome diseaseactivity index (ESSDAI) was used to assess the disease activity of pSS, and ESSDAI ≥5 was defined as moderate to high activity.
💡
Conclusion & Impact:The relationshipbetween bilirubin and ESSDAI was analyzed by Spearman's correlation analysis and multivariable logistic regression.Results: The median level of serum bilirubin was 9 μmol/L (interquartile range (IQR), 7-13 μmol/L) in pSS patients, much lower than healthy controls(median, IQR, 13, 10-18 μmol/L) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objectives: This study aims to determine the serum bilirubin levels in primary Sjögren's syndrome (pSS) patients and to explore clinical significanceof bilirubin in pSS.Patients and methods: Retrospective analysis of electronic medical records was performed in 97 pSS patients (12 males, 85 females; mean age54±15 years; range, 15 to 91 years) and 100 healthy controls (17 males, 83 females; mean age 51±14 years; range, 25 to 75 years). Serum bilirubin andother variables were compared between pSS patients and healthy controls. The European League Against Rheumatism Sjögren's syndrome diseaseactivity index (ESSDAI) was used to assess the disease activity of pSS, and ESSDAI ≥5 was defined as moderate to high activity. The relationshipbetween bilirubin and ESSDAI was analyzed by Spearman's correlation analysis and multivariable logistic regression.Results: The median level of serum bilirubin was 9 μmol/L (interquartile range (IQR), 7-13 μmol/L) in pSS patients, much lower than healthy controls(median, IQR, 13, 10-18 μmol/L) (p
🔖
Cite This Article
XIE, J., ZHANG, Z., LIANG, Y., YANG, Z. (2022). Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome. Archives of Rheumatology, Cilt: 35 - Sayı: 3, 351–356. https://ajindex.com/articles/448027
Mariette X, Criswell LA. Primary Sjögren's Syndrome. N Engl J Med 2018;378:931-9.
Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72.
Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H, et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 2010;62:551-8.
Kurimoto C, Kawano S, Tsuji G, Hatachi S, Jikimoto T, Sugiyama D, et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. J Rheumatol 2007;34:2035-43.
Norheim KB, Jonsson G, Harboe E, Hanasand M, Gøransson L, Omdal R. Oxidative stress, as measured by protein oxidation, is increased in primary Sjøgren's syndrome. Free Radic Res 2012;46:141-6.
Pagano G, Castello G, Pallardó FV. Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res 2013;47:71-3.
Wakamatsu TH, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim OM, et al. Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Invest Ophthalmol Vis Sci 2013;54:201-10.
Boon AC, Hawkins CL, Coombes JS, Wagner KH, Bulmer AC. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med 2015;86:259-68.
Basiglio CL, Toledo FD, Boaglio AC, Arriaga SM, Ochoa JE, Sánchez Pozzi EJ, et al. Physiological concentrations of unconjugated bilirubin prevent oxidative stress-induced hepatocanalicular dysfunction and cholestasis. Arch Toxicol 2014;88:501-14.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.